Jeffrey S. Mathiesen
Jeffrey S. Mathiesen's purchase track record
Jeffrey S. Mathiesen has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/17/2021 | HSDT | $16K | -35.7% | -69.9% | -20.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Solana Company Faces Analyst Target Shift and Rumor Collapse. Solana Company (HSDT) saw mixed analyst activity. Morgan Stanley cut its target to $6, while B. Riley lifted its to $4. Rumors of an Alpenglow mainnet launch fell apart after developers said 'No Alpenrush'. An options market analysis suggested a potential spike. The company also highlighted that its key metric is SOL per share.
Transaction History
| NMTC | ▲ Buy | Grant | 41,929 | $0 | 4/3/2026 | View on chart |
| NMTC | ▲ Buy | Grant | 27,778 | $0 | 2/14/2025 | View on chart |
| NMTC | ▲ Buy | Grant | 20,576 | $0 | 3/16/2023 | View on chart |
| NMTC | ▲ Buy | Grant | 29,240 | $0 | 5/31/2022 | View on chart |
| HSDT | ▲ Buy | Grant | 8,011 | $0 | 2/16/2022 | View on chart |
| HSDT | ▲ Buy | Open Market | 3,000 | $16K | 12/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
NeuroOne Reports Strong Q4 Sales, New $4.5M Order
NeuroOne Medical Technologies said its Q4 sales were about $3.8 million, up 38% from last year. The company also added a $4.5 million purchase order in September and expects FY26 sales of roughly $10.5 million, a 15.6% increase year‑over‑year. These results come as the share price sits near its 12‑touch support level of $1.63 and an RSI of 45.8.
NeuroOne Reports Strong Q4 Sales, New $4.5M Order. NeuroOne Medical Technologies said its Q4 sales were about $3.8 million, up 38% from last year. The company also added a $4.5 million purchase order in September and expects FY26 sales of roughly $10.5 million, a 15.6% increase year‑over‑year. These results come as the share price sits near its 12‑touch support level of $1.63 and an RSI of 45.8.